TGFbDNRII-transduced autologous tumor infiltrating lymphocytes

TGFbDNRII-transduced autologous tumor infiltrating lymphocytes (also referred to as NY-ESO-1 TCR/dnTGFbetaRII T cells) is an autologous T-cell therapy genetically engineered to express a T-cell receptor (TCR) specific for the NY-ESO-1 antigen and a dominant-negative TGF-beta receptor type II (dnTGFbetaRII). Developed by the Roswell Park Comprehensive Cancer Center, this therapy targets NY-ESO-1-expressing solid tumors, including melanoma, synovial sarcoma, and ovarian cancer. The NY-ESO-1 TCR enables the T cells to specifically recognize and eliminate tumor cells presenting the NY-ESO-1 peptide. The addition of the dnTGFbetaRII is a strategic modification designed to shield the T cells from the immunosuppressive effects of TGF-beta, a cytokine prevalent in the tumor microenvironment that typically inhibits T-cell activation and proliferation. By blocking this inhibitory signaling, the therapy aims to enhance the persistence, expansion, and anti-tumor efficacy of the engineered T cells.

Other names

TGFbDNRII-transduced autologous tumor infiltrating lymphocytesautologous NY-ESO-1 TCR/dnTGFbetaRII transgenic T cellsNY-ESO-1 TCR/dnTGFbetaRII T cells